Pharmacogenetics, pharmacogenomics and airway disease

The availability of a draft sequence for the human genome will revolutionise research into airway disease. This review deals with two of the most important areas impinging on the treatment of patients: pharmacogenetics and pharmacogenomics. Considerable inter-individual variation exists at the DNA l...

Full description

Bibliographic Details
Main Author: Hall, Ian P.
Format: Article
Published: 2002
Online Access:https://eprints.nottingham.ac.uk/123/
_version_ 1848790346069180416
author Hall, Ian P.
author_facet Hall, Ian P.
author_sort Hall, Ian P.
building Nottingham Research Data Repository
collection Online Access
description The availability of a draft sequence for the human genome will revolutionise research into airway disease. This review deals with two of the most important areas impinging on the treatment of patients: pharmacogenetics and pharmacogenomics. Considerable inter-individual variation exists at the DNA level in targets for medication, and variability in response to treatment may, in part, be determined by this genetic variation. Increased knowledge about the human genome might also permit the identification of novel therapeutic targets by expression profiling at the RNA (genomics) or protein (proteomics) level. This review describes recent advances in pharmacogenetics and pharmacogenomics with regard to airway disease
first_indexed 2025-11-14T18:11:09Z
format Article
id nottingham-123
institution University of Nottingham Malaysia Campus
institution_category Local University
last_indexed 2025-11-14T18:11:09Z
publishDate 2002
recordtype eprints
repository_type Digital Repository
spelling nottingham-1232020-05-04T20:32:23Z https://eprints.nottingham.ac.uk/123/ Pharmacogenetics, pharmacogenomics and airway disease Hall, Ian P. The availability of a draft sequence for the human genome will revolutionise research into airway disease. This review deals with two of the most important areas impinging on the treatment of patients: pharmacogenetics and pharmacogenomics. Considerable inter-individual variation exists at the DNA level in targets for medication, and variability in response to treatment may, in part, be determined by this genetic variation. Increased knowledge about the human genome might also permit the identification of novel therapeutic targets by expression profiling at the RNA (genomics) or protein (proteomics) level. This review describes recent advances in pharmacogenetics and pharmacogenomics with regard to airway disease 2002 Article PeerReviewed Hall, Ian P. (2002) Pharmacogenetics, pharmacogenomics and airway disease. Respiratory Research, 3 (1). p. 10.
spellingShingle Hall, Ian P.
Pharmacogenetics, pharmacogenomics and airway disease
title Pharmacogenetics, pharmacogenomics and airway disease
title_full Pharmacogenetics, pharmacogenomics and airway disease
title_fullStr Pharmacogenetics, pharmacogenomics and airway disease
title_full_unstemmed Pharmacogenetics, pharmacogenomics and airway disease
title_short Pharmacogenetics, pharmacogenomics and airway disease
title_sort pharmacogenetics, pharmacogenomics and airway disease
url https://eprints.nottingham.ac.uk/123/